HER2 testing in breast carcinoma: Very low concordance rate between reference and local laboratories in Brazil
Abstract
Breast cancer accounts for approximately one quarter of all cancers in females. HER2 gene amplification or HER2 protein overexpression, detected in about 20% of breast carcinomas, predicts a more aggressive clinical course and determines eligibility for targeted therapy with trastuzumab. HER2 testing has become an essential part of the clinical evaluation of all breast carcinoma patients, and accurate HER2 results are critical in identifying patients who may be benefited from targeted therapy. This study investigated the concordance in the results of HER2 immunohistochemistry assays performed in 500 invasive breast carcinomas between a reference laboratory and 149 local laboratories from all geographic regions of Brazil. Our results showed an overall poor concordance (171 of 500 cases, 34.2%) regarding HER2 results between local and reference laboratories, which may be related to the low-volume load of HER2 assays, inexperience with HER2 scoring system, and/or technical issues related to immunohistochemistry in local laboratories. Standardization of HER2 testing with rigorous quality control measures by local laboratories is highly recommended to avoid erroneous treatment of breast cancer patients. Copyright © 2011 by Lippincott Williams & Wilkins.
Publication Title
Applied Immunohistochemistry and Molecular Morphology
Recommended Citation
Wludarski, S., Lopes, L., Berto E Silva, T., Carvalho, F., Weiss, L., & Bacchi, C. (2011). HER2 testing in breast carcinoma: Very low concordance rate between reference and local laboratories in Brazil. Applied Immunohistochemistry and Molecular Morphology, 19 (2), 112-118. https://doi.org/10.1097/PAI.0b013e3181f0b044
